The TH17 helper cells of the immune system have a dark side: they mediate autoimmune disorders. Two drugs that prevent the differentiation and activity of these cells might be of therapeutic value. See Letters p.486 & p.491
Your institute does not have access to this article
Access options
Subscribe to Journal
Get full journal access for 1 year
$199.00
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
Huh, J. R. et al. Nature 472, 486–490 (2011).
Solt, L. A. et al. Nature 472, 491–494 (2011).
Ivanov, I. I. et al. Cell 126, 1121–1133 (2006).
Jetten, A. M. Nucl. Recept. Signal. 7, e003 (2009).
Yang, X. O. et al. Immunity 28, 29–39 (2008).
Kumar, N. et al. Mol. Pharmacol. 77, 228–236 (2010).
O'Connor, W. Jr, Zenewicz, L. A. & Flavell, R. A. Nature Immunol. 11, 471–476 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jetten, A. A helping hand against autoimmunity. Nature 472, 421–422 (2011). https://doi.org/10.1038/472421a
Published:
Issue Date:
DOI: https://doi.org/10.1038/472421a
Further reading
-
Highlights of the advances in basic immunology in 2011
Cellular & Molecular Immunology (2012)
-
ROR blockers inhibit TH17 cells
Nature Reviews Neurology (2011)